Fighting lymphatic filariasis in Madagascar: Lives transformed and hope restored.

WHO and Madagascar’s Ministry of Public Health have expanded services against lymphatic filariasis, achieving full national mass drug coverage in 2023 and training 348 health workers between September and December 2025 to strengthen patient care and surgical capacity.

A health effort in Madagascar is expanding care for people affected by lymphatic filariasis, a mosquito‑transmitted disease that can cause persistent swelling and, in some men, hydrocele. Patients, health workers and WHO report improvements after recent training, surgical services and community campaigns. WHO has worked with the Ministry of Public Health since 2023 to interrupt transmission and to support care for those already affected. Local accounts from Fitovinany describe restored mobility, return to work and reduced stigma after treatment and surgery. Key facts: - The number of endemic districts declined from 96 (2018–2020) to 87 in 2023, with four districts in the post‑treatment phase. - The 2023 national survey recorded 15,303 cases of lymphoedema and 14,069 cases of hydrocele. - Madagascar achieved full national mass drug administration coverage for the first time in 2023, followed by surveys to assess impact. - Between September and December 2025, 348 health professionals were trained, including 17 surgeons with hydrocele specialization. - In October 2025, 61 people received surgery related to lymphatic filariasis in Tamatave (22) and Manakara (39). - Community health workers conduct active screening, mobilization and free surgical interventions in affected districts. Summary: These actions have expanded clinical capacity, increased access to surgical care and reported improvements in daily functioning and social participation for many patients. The next stated step is to continue progressing toward elimination by 2030, consolidating achievements and ensuring sustainability within the health system.